Novo Nordisk Patent Fight With Hims And Hers Puts Valuation In Focus

Simply Wall St

Tue, February 17, 2026 at 2:13 AM GMT+9 2 min read

In this article:

NVO

+1.31%

NONOF

+0.31%

HIMS

+3.16%

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

Novo Nordisk has filed a lawsuit against Hims & Hers Health accusing it of infringing patents related to its obesity drugs.

The case targets compounded, low cost weight loss pills that Novo Nordisk argues are unauthorized copies of its treatments.

The dispute puts a spotlight on how branded drugmakers respond to copycat obesity medications and on how these products are regulated and priced in the U.S.

For investors following Novo Nordisk (CPSE:NOVO B), the legal move comes at a time when the share price stands at DKK310.6. The stock has seen a 20.1% decline over the past 30 days and is down 5.9% year to date, while still showing a 51.5% gain over 5 years. This mix of recent weakness and longer term appreciation frames how the market may weigh legal risks against the company’s established position in obesity treatments.

Looking ahead, the outcome of this lawsuit could influence how copycat obesity drugs are offered and priced, as well as how strictly patents are enforced in this space. For you as an investor, the case may be one factor to watch alongside broader issues such as patient access, regulatory scrutiny, and how competitors respond to Novo Nordisk’s stance on intellectual property.

Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.

CPSE:NOVO B 1-Year Stock Price Chart

Is Novo Nordisk’s balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis.

Quick Assessment

**✅ Price vs Analyst Target**: At DKK310.6, the share price sits about 18% below the DKK379.4 analyst consensus target.

**✅ Simply Wall St Valuation**: The shares are flagged as trading 65.4% below an estimated fair value.

**❌ Recent Momentum**: The stock has logged a 20.1% decline over the past 30 days.

To decide whether to buy, sell or hold Novo Nordisk, you can review Simply Wall St’s company report for the latest analysis of Novo Nordisk’s Fair Value.

Key Considerations

📊 The lawsuit signals that Novo Nordisk is actively defending its obesity drug franchise, which is central to its current investment story.

📊 It may be useful to monitor legal timelines, any impact on prescription volumes, and how pricing of compounded alternatives evolves in the U.S. market.

⚠️ A key risk is that ongoing legal disputes could introduce uncertainty around future cash flows if copycat products remain widely available.

 






Story Continues  

Dig Deeper

For a fuller picture, including more risks and potential rewards, you can review the complete Novo Nordisk analysis. You can also visit the community page for Novo Nordisk to see how other investors believe this latest news affects the company’s narrative.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include NOVO-B.CO.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info